Combined point mutations in codon 12 and 13 of KRAS oncogene in prostate carcinomas
- 172 Downloads
Prostate cancer is a common malignancy that develops by structural mutation(s) and/or other genetic alterations in specific genes.The G to T transversions in codon 12 and C to T transitions in codon 13 of KRAS proto-oncogene are predominant point mutations that occur in about 20% of different cancers in human. In the current study it was aimed to investigate the prevalence and predictive significance of KRAS mutations in patients with prostate carcinomas. In a total of 30 fresh tumoural tissue specimens were investigated in patients with prostate carcinoma. All tumoural specimens were histo-pathologically diagnosed and genotyped for codon 12, 13 KRAS point mutations by reverse hybridisation and direct sequencing methods. KRAS mutations were found in 12 (40%) samples with 29 samples deriving from adenocarcinomas and 1 sample was small cell prostate carcinoma. In 1 (3.44%) sample codon 12 was found to be mutated and in 2 (6.8%) samples codon 13 and in 9 (31%) samples combined codon 12 and 13 were found to be mutated particularly in higher grade of tumoural tissues. Our study, based on representative collection of human prostate tumours, indicates that combined mutations in codons 12 and 13 KRAS are relatively infrequent and most commonly occur in prostate carcinomas.
KeywordsProstate carcinoma Combined point mutation KRAS proto-oncogene Codon 12 and 13
Conflict of interest
There is no conflict of interest that could be perceived as prejudicing the impartiality of the current results.
- 2.Eisenberg ML, Park Y, Brinton LA, Hollenbeck AR, Schatzkin A (2010) Fatherhood and incident prostate cancer in a prospective US cohort. Int J Epidemiol. [Epub ahead of print]Google Scholar
- 3.Heidenreich A, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V,et,al. (2010) EAU Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Treatment of Clinically Localised Disease. Eur Urol. [Epub ahead of print]Google Scholar
- 4.Catalona WJ, Richie JP, Ahmann FR, Hudson MA, Scardino PT, Flanigan RC et al (1994) Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J Urol 151(5):1283–1290PubMedGoogle Scholar
- 6.Ma CG, Ye DW, Yao XD, Zhang SL, Dai B, Zhang HL et al. (2010) The survival analysis of metastatic prostate cancer. Zhonghua Wai Ke Za Zhi. (15):1166–1169Google Scholar
- 26.Schulz WA, Hoffmann MJ (2009) Epigenetic mechanisms in the biology of prostate cancer. Semin Cancer Biol 12:172–180Google Scholar